{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:14:02Z","timestamp":1790144042071,"version":"4.0.1"},"reference-count":81,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T00:00:00Z","timestamp":1429833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122171","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T14:03:24Z","timestamp":1429884204000},"page":"e0122171","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Xuqin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"e49991","DOI":"10.1371\/journal.pone.0049991","article-title":"Low prevalence of Pneumocystis pneumonia (PCP) but high prevalence of pneumocystis dihydropteroate synthase (dhps) gene mutations in HIV-infected persons in Uganda","volume":"7","author":"SM Taylor","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab","volume":"144","author":"I Martin-Garrido","year":"2013","journal-title":"Chest"},{"issue":"4","key":"ref3","first-page":"E162","article-title":"Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review","volume":"5","author":"XQ Jiang","year":"2013","journal-title":"J Thorac Dis"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1600-0609.2007.00994.x","article-title":"Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma","volume":"80","author":"AC Venhuizen","year":"2008","journal-title":"Eur J Haematol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.6004\/jnccn.2006.0025","article-title":"Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology","volume":"4","author":"AD Zelenetz","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3960\/jslrt.50.159","article-title":"Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab","volume":"50","author":"T Kurokawa","year":"2010","journal-title":"J Clin Exp Hematop"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"D Ennishi","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"ref8","first-page":"700","article-title":"Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies","volume":"90","author":"C Tam","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428191003699860","article-title":"High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone","volume":"51","author":"S Kamel","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystic jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"A Kolstad","year":"2007","journal-title":"haematologica"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clml.2011.06.011","article-title":"Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma","volume":"11","author":"H Kato","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"M Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"M Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"19","key":"ref14","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"TM Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"M Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"RI Fisher","year":"1993","journal-title":"N Engl J Med"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"H Katsuya","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hon.947","article-title":"Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab","volume":"29","author":"T Kurokawa","year":"2011","journal-title":"Hematol Oncol"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.12135","article-title":"Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis","volume":"91","author":"GM Haeusler","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000334113","article-title":"The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim\/sulfamethoxazole: a single-center experience","volume":"127","author":"E Hardak","year":"2012","journal-title":"Acta Haematol"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","article-title":"Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy","volume":"51","author":"K Hashimoto","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-012-1592-1","article-title":"Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy","volume":"92","author":"T Kim","year":"2012","journal-title":"Ann Hematol"},{"issue":"15","key":"ref23","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"DF Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref24","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"GA SB Wells","journal-title":"Ohri website"},{"key":"ref25","article-title":"Cochrane handbook for systematic reviews of interventions Version 5.1.0","author":"J Higgins","year":"2011","journal-title":"Cochrane Collaboration"},{"issue":"7414","key":"ref26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"British Medical Journal"},{"issue":"7626","key":"ref27","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","article-title":"Uncertainty in heterogeneity estimates in meta-analyses","volume":"335","author":"JPA Ioannidis","year":"2007","journal-title":"British Medical Journal"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"MJ Bradburn","year":"2007","journal-title":"Stat Med"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0272-5231(03)00134-5","article-title":"Drug-induced pulmonary infection","volume":"25","author":"DA White","year":"2004","journal-title":"Clin Chest Med"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy\u2014rare but there!","volume":"50","author":"R Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/10428191003715377","article-title":"A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?","volume":"51","author":"T Tadmor","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-associated infections","volume":"47","author":"JC Gea-Banacloche","year":"2010","journal-title":"Semin Hematol"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"VA Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"T Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"H Green","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"9\u201310","key":"ref36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10354-004-0067-y","article-title":"Opportunistic infections after treatment with monoclonal antibodies","volume":"154","author":"OA Cornely","year":"2004","journal-title":"Wien Med Wochenschr"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","article-title":"Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome","volume":"28","author":"M Sato","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00467-013-2457-0","article-title":"Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome","volume":"28","author":"P Czarniak","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1600-6143.2008.02151.x","article-title":"Didactic lessons from the serum lactate dehydrogenase posttransplant: a clinical vignette","volume":"8","author":"R Boothpur","year":"2008","journal-title":"Am J Transplant"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","article-title":"Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection","volume":"14","author":"E Shelton","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"ref41","article-title":"Outcomes of Combination Therapy for Chronic Antibody-Mediated Rejection in Renal Transplantation","author":"MG Kim","year":"2013","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-3062.2008.00345.x","article-title":"Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient","volume":"11","author":"D Kumar","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1054-8807(02)00126-6","article-title":"Isolated pleural PTLD after cardiac transplantation","volume":"11","author":"M Lamba","year":"2002","journal-title":"Cardiovasc Pathol"},{"key":"ref44","article-title":"Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients","author":"L Perez-Ordono","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1016\/j.transproceed.2009.02.094","article-title":"A survival case of ABO-incompatible liver transplantation complicated with severe preoperative infection and subsequent overwhelming postsplenectomy infection","volume":"41","author":"K Takeda","year":"2009","journal-title":"Transplant Proc"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/0961203312436855","article-title":"Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy","volume":"21","author":"M-J Tsai","year":"2013","journal-title":"Lupus"},{"issue":"8","key":"ref47","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/ken234","article-title":"Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis","volume":"47","author":"LL Teichmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/0961203312436855","article-title":"Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy","volume":"21","author":"MJ Tsai","year":"2012","journal-title":"Lupus"},{"key":"ref49","article-title":"Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy","author":"F Bonilla-Abadia","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"9","key":"ref50","first-page":"697","article-title":"Rituximab therapy for severe pediatric systemic lupus erythematosus","volume":"50","author":"GX Su","year":"2012","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.amjoto.2012.01.006","article-title":"Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia","volume":"33","author":"MD Otremba","year":"2012","journal-title":"Am J Otolaryngol"},{"key":"ref52","first-page":"448","article-title":"Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","author":"XC Badoux","year":"2011"},{"issue":"8","key":"ref53","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2011-03-341032","article-title":"Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia","volume":"118","author":"XC Badoux","year":"2011","journal-title":"Blood"},{"key":"ref54","article-title":"Fludarabine as Therapy in Chronic Lymphocytic Leukemia (CLL) in Patients over 70 Years","author":"GF Conte","year":"2002"},{"key":"ref55","first-page":"1341","article-title":"The REVLIRIT CLL5 AGMT Study\u2014a Phase I\/II Trial Combining Fludarabine\/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab\/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis","author":"A Egle","year":"2009"},{"key":"ref56","first-page":"232A","article-title":"Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101","author":"TS Lin","year":"2007"},{"key":"ref57","first-page":"233A","article-title":"Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) Receiving fludarabine-based therapy: A comparative analysis of 3 cancer and leukemia group B studies (CALGB 9011,9712,19901)","author":"VA Morrison","year":"2007"},{"issue":"8","key":"ref58","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","article-title":"Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab","volume":"113","author":"CS Zent","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ajh.21341","article-title":"Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases","volume":"84","author":"G Bussone","year":"2009","journal-title":"Am J Hematol"},{"issue":"11","key":"ref60","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","volume":"4","author":"DG Motto","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"ref61","first-page":"644a","article-title":"Activity of alemtuzumab (Mabcampath) in relapsed\/refractory Waldenstrom's macroglobulinemia","author":"RG Owen","year":"2003"},{"issue":"16","key":"ref62","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia","volume":"113","author":"SP Treon","year":"2009","journal-title":"Blood"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.20279","article-title":"Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis","volume":"62","author":"B Hugle","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"ref64","first-page":"1415","article-title":"Infectious toxicity using alemtuzumab","volume":"89","author":"A Nosari","year":"2004","journal-title":"Haematologica"},{"issue":"5","key":"ref65","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6602412","article-title":"An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital","volume":"92","author":"LJ Worth","year":"2005","journal-title":"Br J Cancer"},{"issue":"3","key":"ref66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3899\/jrheum.110994","article-title":"Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study","volume":"39","author":"M Harigai","year":"2012","journal-title":"J Rheumatol"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000261020","article-title":"Granulomatous Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma: case report and review of the literature","volume":"123","author":"H Chang","year":"2010","journal-title":"Acta Haematol"},{"issue":"4","key":"ref68","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-008-0168-2","article-title":"Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature","volume":"88","author":"H Yokoyama","year":"2008","journal-title":"Int J Hematol"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1726-4901(08)70173-4","article-title":"Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab","volume":"71","author":"H Chang","year":"2008","journal-title":"J Chin Med Assoc"},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jinf.2011.04.008","article-title":"Chronic Pneumocystis jiroveci presenting as asymptomatic granulomatous pulmonary nodules in lymphoma","volume":"62","author":"N Kumar","year":"2011","journal-title":"J Infect"},{"issue":"3","key":"ref71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-2006-933433","article-title":"Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia","volume":"218","author":"K Beltz","year":"2006","journal-title":"Klin Padiatr"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.leukres.2011.07.014","article-title":"Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma","volume":"35","author":"SJ Carter","year":"2011","journal-title":"Leuk Res"},{"issue":"13","key":"ref73","first-page":"767","article-title":"Rash, fever, eosinophilia and elevated liver enzymes. DRESS syndrome (drug reaction or rash with eosinophilia and systemic symptoms)","volume":"99","author":"A Derungs","year":"2010","journal-title":"Praxis (Bern 1994)"},{"issue":"9","key":"ref74","first-page":"1049","article-title":"Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma","volume":"46","author":"T Iguchi","year":"2005","journal-title":"Rinsho Ketsueki"},{"issue":"6","key":"ref75","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3816\/CLM.2009.n.087","article-title":"Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma","volume":"9","author":"H Kato","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"ref76","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"E Brusamolino","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"ref77","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","article-title":"Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States","volume":"162","author":"M Kavcic","year":"2013","journal-title":"J Pediatr"},{"issue":"1","key":"ref78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/10428194.2010.525726","article-title":"The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis","volume":"52","author":"A Isidori","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"ref79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3904\/kjim.2010.25.1.86","article-title":"Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab","volume":"25","author":"KH Lim","year":"2010","journal-title":"Korean J Intern Med"},{"issue":"10","key":"ref80","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-011-1268-2","article-title":"Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma","volume":"90","author":"YC Huang","year":"2011","journal-title":"Ann Hematol"},{"issue":"10","key":"ref81","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection","volume":"176","author":"FE Lund","year":"2006","journal-title":"J Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T22:18:18Z","timestamp":1566598698000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122171"}},"subtitle":[],"editor":[{"given":"Herbert B.","family":"Tanowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122171","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,24]]}}}